Effect of Rosuvastatin on Amnesia and Orientation Through Galveston Outcome Amnesia Test in Moderate Head Injury

Condition(s) targeted: Head Injury

Intervention: rosuvastatin (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Universidad Autonoma de San Luis Potosí

Official(s) and/or principal investigator(s):
Jaime Torres-Corzo, Neurosurgeon, Study Director, Affiliation: Hospital Central "Dr. Ignacio Morones Prieto"
Humberto Tapia-Perez, MD, Principal Investigator, Affiliation: Facultad de Medicina UASLP

The purpose of this study is to determine whether rosuvastatin is effective in the management of moderate head injury by improving amnesia and orientation.

Official title: Phase II Study of Rosuvastatin´s Effect on Amnesia and Orientation Through Galveston Outcome Amnesia Test in Humans With Moderate Head Injury

Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Single Group Assignment, Efficacy Study

Primary outcome:

Galveston Orientation and Amnesia Test

Lesion by CT scan

Secondary outcome:

Changes Glasgow Coma Scale

Functional outcome by Disability Rating Scale

Cytosines (Il-1B, IL-6, TNF-alfa)

acute reanal Insuficience

Detailed description: The head injury is a frequent problem of health, which produces high morbid-mortality. Today is the main cause of death and disability between 18 and 40 years. In addition it originates expensive expenses in health care systems.

Head injury produces damage by primary mechanisms related to impact, then by biochemical ways which are activated and they carry to secondary damage. Many studies have been conducted for explaining secondary injury, the majority conclude there is a kind of ischemic lesion related maybe with changes in cerebral flow and metabolism. The management today is trying to avoid progression in secondary damage without good outcome. Many drugs and measures has been ineffective.

In the last years has been demonstrated in head injury microvascular damage like stroke. Statins o inhibitors of HMG CoA reductase are drugs used in dyslipidemia, frequently for reduction in LDL. Experimental and clinical studies in stroke have shown improvement in outcome. The toxicity related to statin is myopathy and hepatopathy, both with low incidence without fatal cases. Rosuvastatin has been postulated be the most powerful with longest life and toxicity similar to another statins.

We have designed this study for demonstrate if the administration of rosuvastatin in the first 24 hours and by 10 days has improvement in amnesia and orientation, furthermore outcome.

Minimum age: 16 Years. Maximum age: 50 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Man or woman >16 and <50 years with HI less 24 hours in progression and Glasgow

between 9 y 12.

- Man or woman >16 and <50 years with HI and Glasgow l3, with lesions in TC scan.

- Acceptance of family to participate (first grade).

Exclusion Criteria:

- History of HI with disability

- History of neurological or psychiatric disease with disability.

- Administration 24 hrs previous of: fibrates, niacin, ciclosporin, azoles, macrolides,

inhibitors of protease, nefazodone, verapamil, diltiazem,amiodarone.

- Existence of systemic injury with life in compromise (massive bleeding, exposition of

bone in fracture, hepatic or splenic laceration or in great vessels and shock).

- Administration of THAM, mannitol, barbiturates, corticosteroids, scavengers of free

radicals, inhibitors of lipidic peroxidation, indometacin, calcium antagonist, antagonists of neurotransmitters

- Existence of intracranial lesion which needs surgery.

- Lesions not classifiable or in brainstem.

- Allergy to the drug.

- Hepatopathy or myopathy (or) history of this, or clinical data of hepatic disease.

- Management previous in other Hospital.

- Pregnancy

Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosi 78240, Mexico

Related publications:

Tapia-Perez H, Sanchez-Aguilar M, Torres-Corzo J, Rodriguez-Leyva I, Herrera-Gonzalez LB. [Statins and brain protection mechanisms.] Rev Neurol. 2007 Sep 16-30;45(6):359-64. Spanish.

Starting date: July 2006
Ending date: September 2007
Last updated: February 25, 2008